Special Issue "Advances in Rhabdomyosarcoma"
A special issue of Cells (ISSN 2073-4409).
Deadline for manuscript submissions: 30 September 2021.
Interests: epigenetics; targeted therapy; regenerative medicine; molecular and cellular biology; network medicine; genetics
Special Issues and Collections in MDPI journals
Rhabdomyosarcoma (RMS) is the most commonly diagnosed malignant soft tissue tumour in paediatric age, with alveolar RMS (ARMS) and embryonal RMS (ERMS) representing the two main histological subtypes. Despite the improvement in standardized therapeutic protocols, involving surgery, chemotherapy and radiotherapy, patients with metastatic or recurrent disease have a poor clinical outcome with a 5-year overall survival of about 30%. So, the discovery of innovative therapies against RMS is an absolute clinical priority. To this concern, the definition of the specific altered coding and non-coding genes, as well as the precise molecular mechanisms playing role in their aberrant expression and in tumour–microenvironment communication may represent a more focused solution that can help finding new biomarkers and setting novel targeted therapies against RMS. The aim of the present Special Issue is to assemble recent advancements into the in vitro and in vivo effects of a novel generation of antitumoral molecules (epigenetic drugs, microRNAs, small inhibitors), as single agents and in combination with conventional treatments or immunotherapy. Because complex systems, such as malignancies, can be more thoroughly defined if considered as a whole, "omics" approaches will be particularly appreciated for the identification, the characterization and quantification of the drug-related molecular properties. Particular interest will be given to the antitumoral effects against cancer stem cells (CSCs), which have a pivotal role in the acquired therapy resistance associated with RMS progression and relapse, as well as poor clinical outcomes in cancer patients. Rapidly emerging data have the potential to be translated into more efficient and less toxic personalized treatments for the clinical care of RMS patients.
We look forward to your contributions to this Special Issue (Cells; IF: 4.366, ISSN 2073-4409) in the form of original research articles and reviews.
Dr. Francesca Megiorni
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- targeted therapy
- antitumoral molecules
- “omics” analysis